Cost‐Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers
Abstract Early detection of hepatocellular carcinoma (HCC) in patients with liver cirrhosis (LC) and/or hepatitis virus B/C infection (HVI) improves survival, highlighting the need for accurate, affordable diagnostic tools. Here, 11 methylated DNA markers (MDMs) are identified during marker discover...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-05-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202411945 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850270252670124032 |
|---|---|
| author | Tian Yang Mingda Wang Nanya Wang Mingxin Pan Yu Xu Qiancheng You Lanqing Yao Jiahao Xu Lihui Gu Xiaodong Sun Lei Zhang Jiayue Xu Bingsi Li Guoqiang Wang Shangli Cai Guoyue Lv Feng Shen |
| author_facet | Tian Yang Mingda Wang Nanya Wang Mingxin Pan Yu Xu Qiancheng You Lanqing Yao Jiahao Xu Lihui Gu Xiaodong Sun Lei Zhang Jiayue Xu Bingsi Li Guoqiang Wang Shangli Cai Guoyue Lv Feng Shen |
| author_sort | Tian Yang |
| collection | DOAJ |
| description | Abstract Early detection of hepatocellular carcinoma (HCC) in patients with liver cirrhosis (LC) and/or hepatitis virus B/C infection (HVI) improves survival, highlighting the need for accurate, affordable diagnostic tools. Here, 11 methylated DNA markers (MDMs) are identified during marker discovery. In phase I, each selected MDM is validated in 175 plasma samples (HCC, n = 85; LC/HVI, n = 72) by the CO‐methylation aMplification rEal‐Time PCR (COMET) assay. Of these, 8 MDMs are qualified for phase II study, where a logistic regression model (COMET‐LR) is trained and validated with 336 plasma samples (HCC, n = 211; LC/HVI, n = 113; training vs validation, 2:1). In the validation, the COMET‐LR achieved 90.0% sensitivity at 97.4% specificity. Notably, sensitivity in patients with TNM stage I, diameter<3 cm, AFP‐negative (<20 ng mL−1), PIVKA‐II‐negative (<40 mAU mL−1) is 82.4%, 77.8%, 88.6%, and 85.7%, respectively. The COMET‐LR outperformed multiple protein markers (AFP, AFP‐L3, and PIVKA‐II) and published scores for HCC screening (GALAD, Doylestown, and ASAP), in terms of both sensitivity and specificity. The assay represents a significant advancement in addressing the unmet need for accurate, non‐invasive, accessible, and cost‐effective early detection tools for LC/HVI individuals. Further validation in a prospective cohort is warranted. |
| format | Article |
| id | doaj-art-2aadaaf247d34f308cc2c0f6bc2fb31f |
| institution | OA Journals |
| issn | 2198-3844 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Science |
| spelling | doaj-art-2aadaaf247d34f308cc2c0f6bc2fb31f2025-08-20T01:52:42ZengWileyAdvanced Science2198-38442025-05-011219n/an/a10.1002/advs.202411945Cost‐Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA MarkersTian Yang0Mingda Wang1Nanya Wang2Mingxin Pan3Yu Xu4Qiancheng You5Lanqing Yao6Jiahao Xu7Lihui Gu8Xiaodong Sun9Lei Zhang10Jiayue Xu11Bingsi Li12Guoqiang Wang13Shangli Cai14Guoyue Lv15Feng Shen16Department of Hepatobiliary Surgery Eastern Hepatobiliary Surgery Hospital Naval Medical University Shanghai 200438 ChinaDepartment of Hepatobiliary Surgery Eastern Hepatobiliary Surgery Hospital Naval Medical University Shanghai 200438 ChinaDepartment of Hepatobiliary and Pancreatic Surgery General Surgery Center First Hospital of Jilin University Changchun Jilin 130021 ChinaDepartment of Hepatobiliary Surgery II General Surgery Center Zhujiang Hospital Southern Medical University Guangzhou 510280 ChinaBurning Rock Biotech Guangzhou 510300 ChinaBurning Rock Biotech Guangzhou 510300 ChinaDepartment of Hepatobiliary Surgery Eastern Hepatobiliary Surgery Hospital Naval Medical University Shanghai 200438 ChinaDepartment of Hepatobiliary Surgery Eastern Hepatobiliary Surgery Hospital Naval Medical University Shanghai 200438 ChinaDepartment of Hepatobiliary Surgery Eastern Hepatobiliary Surgery Hospital Naval Medical University Shanghai 200438 ChinaDepartment of Hepatobiliary and Pancreatic Surgery General Surgery Center First Hospital of Jilin University Changchun Jilin 130021 ChinaBurning Rock Biotech Guangzhou 510300 ChinaBurning Rock Biotech Guangzhou 510300 ChinaBurning Rock Biotech Guangzhou 510300 ChinaBurning Rock Biotech Guangzhou 510300 ChinaBurning Rock Biotech Guangzhou 510300 ChinaDepartment of Hepatobiliary and Pancreatic Surgery General Surgery Center First Hospital of Jilin University Changchun Jilin 130021 ChinaDepartment of Hepatobiliary Surgery Eastern Hepatobiliary Surgery Hospital Naval Medical University Shanghai 200438 ChinaAbstract Early detection of hepatocellular carcinoma (HCC) in patients with liver cirrhosis (LC) and/or hepatitis virus B/C infection (HVI) improves survival, highlighting the need for accurate, affordable diagnostic tools. Here, 11 methylated DNA markers (MDMs) are identified during marker discovery. In phase I, each selected MDM is validated in 175 plasma samples (HCC, n = 85; LC/HVI, n = 72) by the CO‐methylation aMplification rEal‐Time PCR (COMET) assay. Of these, 8 MDMs are qualified for phase II study, where a logistic regression model (COMET‐LR) is trained and validated with 336 plasma samples (HCC, n = 211; LC/HVI, n = 113; training vs validation, 2:1). In the validation, the COMET‐LR achieved 90.0% sensitivity at 97.4% specificity. Notably, sensitivity in patients with TNM stage I, diameter<3 cm, AFP‐negative (<20 ng mL−1), PIVKA‐II‐negative (<40 mAU mL−1) is 82.4%, 77.8%, 88.6%, and 85.7%, respectively. The COMET‐LR outperformed multiple protein markers (AFP, AFP‐L3, and PIVKA‐II) and published scores for HCC screening (GALAD, Doylestown, and ASAP), in terms of both sensitivity and specificity. The assay represents a significant advancement in addressing the unmet need for accurate, non‐invasive, accessible, and cost‐effective early detection tools for LC/HVI individuals. Further validation in a prospective cohort is warranted.https://doi.org/10.1002/advs.202411945chronic hepatitis virus infectionearly detectionhepatocellular carcinomaliver cirrhosismethylated plasma DNA marker |
| spellingShingle | Tian Yang Mingda Wang Nanya Wang Mingxin Pan Yu Xu Qiancheng You Lanqing Yao Jiahao Xu Lihui Gu Xiaodong Sun Lei Zhang Jiayue Xu Bingsi Li Guoqiang Wang Shangli Cai Guoyue Lv Feng Shen Cost‐Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers Advanced Science chronic hepatitis virus infection early detection hepatocellular carcinoma liver cirrhosis methylated plasma DNA marker |
| title | Cost‐Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers |
| title_full | Cost‐Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers |
| title_fullStr | Cost‐Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers |
| title_full_unstemmed | Cost‐Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers |
| title_short | Cost‐Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers |
| title_sort | cost effective identification of hepatocellular carcinoma from cirrhosis or chronic hepatitis virus infection using eight methylated plasma dna markers |
| topic | chronic hepatitis virus infection early detection hepatocellular carcinoma liver cirrhosis methylated plasma DNA marker |
| url | https://doi.org/10.1002/advs.202411945 |
| work_keys_str_mv | AT tianyang costeffectiveidentificationofhepatocellularcarcinomafromcirrhosisorchronichepatitisvirusinfectionusingeightmethylatedplasmadnamarkers AT mingdawang costeffectiveidentificationofhepatocellularcarcinomafromcirrhosisorchronichepatitisvirusinfectionusingeightmethylatedplasmadnamarkers AT nanyawang costeffectiveidentificationofhepatocellularcarcinomafromcirrhosisorchronichepatitisvirusinfectionusingeightmethylatedplasmadnamarkers AT mingxinpan costeffectiveidentificationofhepatocellularcarcinomafromcirrhosisorchronichepatitisvirusinfectionusingeightmethylatedplasmadnamarkers AT yuxu costeffectiveidentificationofhepatocellularcarcinomafromcirrhosisorchronichepatitisvirusinfectionusingeightmethylatedplasmadnamarkers AT qianchengyou costeffectiveidentificationofhepatocellularcarcinomafromcirrhosisorchronichepatitisvirusinfectionusingeightmethylatedplasmadnamarkers AT lanqingyao costeffectiveidentificationofhepatocellularcarcinomafromcirrhosisorchronichepatitisvirusinfectionusingeightmethylatedplasmadnamarkers AT jiahaoxu costeffectiveidentificationofhepatocellularcarcinomafromcirrhosisorchronichepatitisvirusinfectionusingeightmethylatedplasmadnamarkers AT lihuigu costeffectiveidentificationofhepatocellularcarcinomafromcirrhosisorchronichepatitisvirusinfectionusingeightmethylatedplasmadnamarkers AT xiaodongsun costeffectiveidentificationofhepatocellularcarcinomafromcirrhosisorchronichepatitisvirusinfectionusingeightmethylatedplasmadnamarkers AT leizhang costeffectiveidentificationofhepatocellularcarcinomafromcirrhosisorchronichepatitisvirusinfectionusingeightmethylatedplasmadnamarkers AT jiayuexu costeffectiveidentificationofhepatocellularcarcinomafromcirrhosisorchronichepatitisvirusinfectionusingeightmethylatedplasmadnamarkers AT bingsili costeffectiveidentificationofhepatocellularcarcinomafromcirrhosisorchronichepatitisvirusinfectionusingeightmethylatedplasmadnamarkers AT guoqiangwang costeffectiveidentificationofhepatocellularcarcinomafromcirrhosisorchronichepatitisvirusinfectionusingeightmethylatedplasmadnamarkers AT shanglicai costeffectiveidentificationofhepatocellularcarcinomafromcirrhosisorchronichepatitisvirusinfectionusingeightmethylatedplasmadnamarkers AT guoyuelv costeffectiveidentificationofhepatocellularcarcinomafromcirrhosisorchronichepatitisvirusinfectionusingeightmethylatedplasmadnamarkers AT fengshen costeffectiveidentificationofhepatocellularcarcinomafromcirrhosisorchronichepatitisvirusinfectionusingeightmethylatedplasmadnamarkers |